MedTrace Logo

Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia

NCT04100187 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-12-01

No results posted yet for this study

Summary

This study aims to evaluate the safety, efficacy and duration of response of CD19 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in patients with high risk, relapsed CD19+ haematological malignancies.

Conditions

Interventions

BIOLOGICAL

Anti-CD19-CAR

Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)

Sponsors & Collaborators

  • Hebei Yanda Ludaopei Hospital

    collaborator OTHER

  • Kecellitics Biotech Company Ltd

    lead INDUSTRY

Principal Investigators

  • Li xiangqun · Kecellitics Biotech Company Ltd

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2023-08-01
Completion
2024-08-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04100187 on ClinicalTrials.gov